Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes
Sponsor: |
Alliance for Clinical Trials in Oncology |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAR9502 |
U.S. Govt. ID: |
NCT02856581 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
This randomized phase III trial studies how well management of a tobacco treatment intervention works in reducing surgical complications in patients with newly diagnosed lung cancer who smoke cigarettes. Management of a tobacco treatment intervention compares varenicline (a drug that reduces the craving and withdrawal symptoms that occur with abstinence from nicotine) and behavioral interventions consisting of a brief clinician-delivered intervention and tobacco quitline tobacco cessation service available through a toll-free telephone number follow-up with placebo (a pill with no active medication) along with similar behavioral interventions. It is not yet known whether management of a tobacco treatment intervention is more effective in reducing surgical complications than placebo.
This study is closed
Investigator
Bryan Stanifer, MD
Are you 18 years of age or older? |
Yes |
No |
Do you have a new diagnosis of lung cancer and are seeking surgical consult? |
Yes |
No |
Have you smoked daily or nearly every day in the previous 6 months? |
Yes |
No |
Are you motivated to stop smoking? |
Yes |
No |
Can you complete study questionnaires in English? |
Yes |
No |